Adrenocortical, somatotropic, and antidiuretic response to nasal glucagon in healthy subjects
Authors' conclusion
Intranasal glucagon administration is not an effective stimulus for hypophyseal secretion. Hypokalemia secondary to hyperinsulinemic rebound appears to be a frequent complication of its acute administration.
Study context
- Population
- Healthy subjects (50% women)
- Participants
- 10 subjects
- Comparison
- Intranasal glucagon vs placebo
Methodological detailssingle-blinded, cross-over
- Single-blinded
- Cross-over
Primary result
As reported in the abstract
Corticotropic, somatotropic and antidiuretic axis response
- Adrenocorticotropic hormone (ACTH) and cortisol decreased progressively after both glucagon and placebo
- P < 0.001
- Reduction in cortisol less accentuated with glucagon up to +90'
- P < 0.05
- Growth hormone (GH) decreased after placebo
- P < 0.001
- GH increasing, non-significant trend after glucagon
- P = 0.096
- GH difference between groups from +120' onwards
- P < 0.005
Safety
- Hypokalemia (potassium <3.5 mmol/L) post-glucagon
- 6 · events
- Hypokalemia (potassium <3.5 mmol/L) post-glucagon — Potassium nadir at 45'
- 3.6 [3.2-3.8] mmol/L
- Hypokalemia (potassium <3.5 mmol/L) post-glucagon — Nadir correlated with post-glycemic rise insulin peak (Spearman's rho)
- −0.719; P = 0.019
Original publication
Adrenocortical, somatotropic, and antidiuretic response to nasal glucagon in healthy subjects. Eur J Endocrinol. Published 9 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →